Lixte Biotechnology gets Nasdaq extension to Feb 18, 2025 to meet equity requirement

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Nasdaq notified non-compliance with $2.5M minimum stockholders' equity requirement.
Company submitted compliance plan; Nasdaq granted extension until February 18, 2025.
Filed S-1 registration statement to raise up to $4.0M in equity capital.
Failure to evidence compliance by March 31, 2025 may lead to delisting.
Common stock and warrants continue trading on Nasdaq under LIXT and LIXTW.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.